bladder cancer

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

Oncology

Interview at ESMO 2025 with Sandeep Reddy, Immunity Bio

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

News

enGene's president and chief executive, Ron Cooper

Trial sets up filing for enGene bladder cancer gene therapy

enGene is hoping to file its gene for a form of bladder cancer before the end of 2026, based on phase 2 data revealing a 62% complete response rate.

News

J&J claims FDA okay for bladder cancer drug TAR-200

Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout.

News

NICE backs bladder cancer duo that can double survival

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green light for NHS use.

Padcev/Keytruda scores again in early bladder cancer

EMA starts review of 'transformative' bladder cancer therapy

ESMO25: Harnessing the innate and the adaptive immune respon...

Trial sets up filing for enGene bladder cancer gene therapy

J&J claims FDA okay for bladder cancer drug TAR-200

NICE backs bladder cancer duo that can double survival

BioMarin ends year with $4.8bn play for Amicus

How to meet your physicians where they are online

bladder cancer

Editor's Picks